Company intelligence / Profile preview

CALIDAIRE

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Calidi Biotherapeutics is advancing a proprietary platform that uses stem cells to deliver oncolytic viruses directly to tumors. Their approach aims to kill cancer cells locally and stimulate systemic immune responses against metastatic disease. The company has reported promising preclinical results with complete eradication of certain tumors in models and is currently running or initiating multiple Phase 1 clinical trials in solid tumors and high-grade glioma.

Therapeutic areas: Oncology
Modalities: Cell therapyOncolytic virus therapyGene therapy (via viral payload delivery)
Industry: Biotech

Beyond the preview

Go deeper on CALIDAIRE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CALIDAIRE.

Explore the full profile